Entain, the sports-betting and gambling entertainment group, has announced a 7% increase in its net gaming revenue for the third quarter. This follows a 19% growth in the first half of 2023, bringing the total revenue to £2.40 billion ($2.92 billion). The company also stated that it expects to meet or exceed its full-year earnings and revenue targets.
Strong Performance in Online and Retail
Entain reported a 9% rise in net gaming revenue for its online business during the third quarter. Retail sites also experienced a 4% increase in revenue. These results highlight the company's ability to achieve growth across different sectors.
Strategic Plans for Future Growth
CEO Jette Nygaard-Andersen outlined Entain's updated strategic plan, focusing on key areas for organic growth. The plan includes prioritizing high-growth markets like the U.S. and Brazil, driving profitable growth in core markets such as the U.K. and Australia, and exiting smaller non-core operations.
Positive Outlook for Full-Year Results
Entain expressed confidence in meeting the upper end of its full-year total net gaming revenue guidance, which ranges from $1.88 billion to $2.00 billion. The company also expects full-year earnings before interest, taxes, depreciation, and amortization (EBITDA) to fall within the range of £1.00 billion to £1.05 billion.
Entain's commitment to improving operational leverage and increasing EBITDA margins demonstrates its dedication to sustained growth and profitability.
For more information, please visit Entain's official website.
Our Latest News
Helix Acquisition II Increases IPO Size
Helix Acquisition II plans to increase its IPO size, with potential merger plans in the healthcare industry. Affiliated with Cormorant, the company aims for fut...
Stocks Rise in Asia-Pacific Region
Stocks in the Asia-Pacific region experienced an increase on Wednesday, Aug. 30, with the Japanese market showing a third consecutive day of gains. Hong Kong st...
AbbVie Outperforms Revenue Expectations and Raises Sales Outlook for Key Immunology Drugs
AbbVie exceeded revenue expectations in Q4 and updated long-term sales outlook for prominent immunology drugs. Although Humira revenue declined, AbbVie remains...